Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Journey Colab Corp. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, VALLE, ERNESTO, who is the busiest examiner with 1 pending action. The matter is assigned to 1 distinct art unit. The current workload is focused on a single examiner's review, representing the only active point of contact for the portfolio's pending matters at the USPTO.
A practitioner handling this case must focus on the specific examination patterns of VALLE, ERNESTO, as there are no other pending actions to provide alternative paths to allowance. The busiest examiner's workload of 1 pending action matches the total volume of the portfolio's current activity. This lack of diversification across examiners or art units means that any challenges encountered during the prosecution of this single action cannot be mitigated by progress in other cases. The strategy must be precisely aligned with the Biotechnology & Pharmaceuticals standards of the 1 distinct art unit involved. Success in this matter is the sole focus of the current prosecution effort, requiring a highly targeted approach to address the specific concerns of the assigned examiner and the administrative unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720892 | Methods of Treating Substance Use Disorders Using 5-MeO-DMT | VALLE, ERNESTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720892 | Methods of Treating Substance Use Disorders Using 5-MeO-DMT | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720892 | Methods of Treating Substance Use Disorders Using 5-MeO-DMT | VALLE, ERNESTO | 1623 | §103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJourney Colab Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernesto Valle has the most, with 1 of Journey Colab Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
